₹ 1,681.40
21.50 (1.30%)
A
Aurobindo Pharma
₹ 1,681.40
Aurobindo Pharma Share Price Today
Aurobindo Pharma (AUROPHARMA) share price is trading at ₹1,681.40 on the NSE as of October 30, 2026 at 03:55 PM, up by 1.30% from its previous close of ₹1,659.90. In todays trading session AUROPHARMA reached a high of 1,687.00 and low of 1,647.20. The average traded price for today is 1,673.38. The 50 DMA stands at 1,662.60 and 200 DMA is at 1,457.33. Looking at intraday trend, the stock is in Uptrend.
Stock Overview
- Symbol : AUROPHARMA
- Open : ₹1,652.00
- Previous Close : ₹1,659.90
- Day's Range : ₹1,647.20 – ₹1,687.00
- 52-Week Range : ₹1,091.20 – ₹1,740.00
- Upcoming Event : Q2 FY 26-27 Results (4th Nov 2026, Wednesday)
Get 20+ Chart Types, 180+ Indicators, 80+ Drawing Tools & Create Custom Indicators for FREE.
AUROPHARMA Stock Performance
Markets Today
High
1,687.00
Low
1,647.20
Open at
1,652.00
Prev Close
1,659.90
Volumes
9,52,650
Avg Price
1,673.38
Lower Circuit
1,513.30
Upper Circuit
1,849.50
Last Traded Details
Quantity
10
Time
15:55:48
Price Movement
Historical Performance
3 M High
1,740.00
3 M Low
1,536.80
1 Yr High
1,740.00
1 Yr Low
1,091.20
3 Yr High
1,740.00
3 Yr Low
834.65
5 Yr High
1,740.00
5 Yr Low
397.20
1-Year Performance
AUROPHARMA Pros and Cons
EBITDA margin expands from 20.4% in Q1 FY26 to 21.0% in Q1 FY27, confirming improved pricing power and operational efficiency.
Formulation revenue grows from ₹6,953 Cr in Q1 FY26 to ₹8,101 Cr in Q1 FY27, driven by strong demand across Europe and growth markets.
ANDA filings increase from 865 in Q1 FY26 to 896 in Q1 FY27, reflecting a robust pipeline for future US market approvals.
Net debt improves from -₹1,204 Cr in Q1 FY26 to -₹397 Cr in Q1 FY27, demonstrating successful deleveraging and lower interest burden.
Beta-lactam API revenue rises from ₹633 Cr in Q1 FY26 to ₹800 Cr in Q1 FY27, highlighting sustained demand in the core API segment.
Cash and investments fall from ₹10,676 Cr in Q4 FY26 to ₹8,790 Cr in Q1 FY27, signaling a notable liquidity drawdown.
Foreign exchange loans climb from ₹5,299 Cr in Q1 FY26 to ₹7,472 Cr in Q1 FY27, increasing currency risk exposure amid rupee depreciation.
US revenue drops from $420 Mn in Q3 FY26 to $387 Mn in Q4 FY26, indicating temporary sales pressure in the key American market.
Working capital loans rise from $185 Mn in Q1 FY26 to $800 Mn in Q1 FY27, reflecting higher operational funding requirements.
Addressable market size contracts from $197.2 Mn in Q3 FY26 to $182.3 Mn in Q1 FY27, pointing to a shrinking opportunity space in key formulation segments.
AUROPHARMA Analyst Rating
Buy
Analysts have suggested that investors can
Buy this Stock
- By Refinitiv from 26 analysts
Buy
61.54%
Hold
19.23%
Sell
19.23%
Get forecast for Price, ROA & ROE based on analyst ratings.
AUROPHARMA Share Price History
AUROPHARMA Fundamentals
Company Valuation
Market Cap (₹ Cr.)
96,744
PE Ratio
25.70
PB Ratio
2.51
Dividend Yield
0.24%
ROE
9.25%
ROCE
13.58%
Book Value (₹)
658.53
Face Value (₹)
1.00
Analyse AUROPHARMA with 12+ custom fundamentals and financial ratios.
Share Holding Pattern
| Held By | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.88% | 51.88% |
| Domestic Institutional Investors (DII) | 27.60% | 27.68% | 25.87% | 25.10% | 24.42% |
| Foreign Institutional Investors (FII) | 14.21% | 13.94% | 15.24% | 16.38% | 17.41% |
| Public Investors | 5.25% | 5.36% | 5.74% | 5.36% | 5.02% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Promoters
Domestic Institutional Investors (DII)
Foreign Institutional Investors (FII)
Public Investors
Government
Aurobindo Pharma Return Calculator
Note: Past profits do not guarantee future returns.
AUROPHARMA Investment Returns
Short Term
1 Week
1 Month
3 Months
6 Months
9 Months
Long Term
1 Year
2 Years
3 Years
4 Years
5 Years
- In Short Term
- In Long term
1 Week
1 Month
3 Months
6 Months
9 Months
Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.
AUROPHARMA Technicals
Moving Averages
Technical Indicators
Summary of Technical Indicators for AUROPHARMA
Margin on AUROPHARMA
*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).
AUROPHARMA Financials Summary
In Crores
AUROPHARMA Financials
Income Statement
In Cr
Balance Sheet
In Cr
Cash Flow
In Cr
Corporate Actions
The above dates are ex-dates.
Check AUROPHARMA latest Company Filings, Investor Presentation & Conference Call details.
AUROPHARMA Revenue Growth
All values are in Crores
Revenue
Profit
Loss
AUROPHARMA Options Snapshot
AUROPHARMA Futures Snapshot
Use from 12+ Pre-built Strategies or Build Your Own to trade AUROPHARMA FnO contracts.
AUROPHARMA Similar Stocks
FAQs on AUROPHARMA
What is the share price of Aurobindo Pharma?
What is the 52W high and 52W low of Aurobindo Pharma?
What is the return on Aurobindo Pharma share?
- Past 1 year: 51.25%
- Past 3 years: 96.78%
- Past 5 years: 143.91%
What is the PE and PB Ratio of Aurobindo Pharma?
What is the EPS of Aurobindo Pharma?
What is the shareholding pattern of Aurobindo Pharma?
- DIIs - 24.42%
- FII - 17.41%
- Promoters - 51.88%
- Public Investors 5.02%
- Goverenment - 0.00%
How to buy Aurobindo Pharma shares online?
How to buy Aurobindo Pharma shares on Dhan?
- Download the Dhan App to Open a Demat Account
- Navigate to the “Money Tab”
- Add money to your account
- Search for Aurobindo Pharma share
- Tap on “Buy”
Option Chain